Insulin therapy drug resubmitted for FDA approval

10/16/2013 | Pharmaceutical Business Review Online

MannKind again filed an application with the FDA for approval to market its Afrezza inhalation powder, a fast mealtime insulin treatment intended to improve glycemic control for diabetes patients. The application was based on data from two late-stage trials.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN